Thrombotic Microangiopathy
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Where it strikes
Glomerular & peritubular capillaries
Filtration barrier (podocytes + endothelium)
Agents’ overall severity
Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.
Agents’ overall reversibility
Agents’ onset window
How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.
Real-world reporting for this lesion
FAERS across all lesions →How disproportionately thrombotic microangiopathy is reported for each agent in FAERS, against every other drug (reporting odds ratio, 95% CI; a signal needs the lower bound above 1, on at least 50 total reports for the agent) — a spontaneous-reporting signal, not incidence or proven causation. FAERS carries reporting and indication biases and has no denominator.
Documented in the atlas profile and carrying a FAERS signal — the strongest claim the atlas makes.
Documented in a profile with no reporting signal. 13 of 16 sit on a reportable term with enough reports, so FAERS could have flagged the lesion and did not; the rest are expected silences.
A real reporting signal that is not evidence for this drug-lesion pair: no MedDRA term names it, the naming subset asked alone came back flat, or the 2026-08 review attributed the reporting to the population, co-therapy, or class-level literature.
The terms that name this lesion are disproportionate, but no profile documents it for that agent. Most are echoed by a sibling agent in the same class. Leads for review, never lesions the atlas claims.
- Moxetumomab pasudotoxImmunotoxin (anti-CD22 PE38)341.06 (190.22–611.55) · n=14 Reporting signal.
- PentostatinPurine analog (ADA inhibitor) · FAERS only61.13 (40.26–92.84) · n=23 Reporting signal.
- DinutuximabAnti-GD2 antibody40.50 (27.78–59.04) · n=28 Reporting signal.
- SirolimusmTOR inhibitor · FAERS only39.43 (35.74–43.50) · n=423 Reporting signal.
- ThiotepaAlkylator · FAERS only36.92 (32.79–41.58) · n=286 Reporting signal.
- BusulfanAlkylator32.27 (29.20–35.66) · n=406 Reporting signal.
- GemcitabineNucleoside analog32.13 (30.32–34.04) · n=1,290 Reporting signal.
- AmsacrineTopoisomerase II inhibitor (acridine) · FAERS only26.75 (14.31–50.02) · n=10 Reporting signal.
- CarfilzomibProteasome inhibitor26.14 (24.04–28.42) · n=582 Reporting signal.
- FludarabinePurine analog · FAERS only25.91 (24.11–27.84) · n=798 Reporting signal.
- MelphalanAlkylator · FAERS only25.67 (23.48–28.06) · n=512 Reporting signal.
- Denileukin diftitoxImmunotoxin (IL-2–diphtheria) · FAERS only23.92 (3.31–172.68) · n=1 Reporting signal, fragile (few reports).
- IsatuximabAnti-CD38 antibody · FAERS only19.27 (15.68–23.70) · n=92 Reporting signal.
- Mitomycin CAntitumor antibiotic19.05 (14.66–24.77) · n=57 Reporting signal.
- LifileucelTumor-infiltrating lymphocyte (TIL) therapy · FAERS only12.76 (4.09–39.82) · n=3 Reporting signal, fragile (few reports).
- Inotuzumab ozogamicinAntibody-drug conjugate (CD22/calicheamicin) · FAERS only12.58 (8.83–17.93) · n=31 Reporting signal.
- RamucirumabAnti-VEGFR2 antibody8.05 (5.94–10.90) · n=42 Reporting signal.
- EverolimusmTOR inhibitor7.78 (6.96–8.71) · n=314 Reporting signal.
- BevacizumabAnti-VEGF antibody6.10 (5.63–6.61) · n=638 Reporting signal.
- Carmustine (BCNU)Nitrosourea alkylator5.63 (3.70–8.56) · n=22 Reporting signal.
- OxaliplatinPlatinum agent4.75 (4.24–5.34) · n=295 Reporting signal.
- BortezomibProteasome inhibitor4.22 (3.77–4.72) · n=310 Reporting signal.
- DecitabineHypomethylating agent4.07 (2.56–6.46) · n=18 Reporting signal.
- 5-FluorouracilPyrimidine analog3.57 (3.13–4.07) · n=231 Reporting signal.
- RuxolitinibJAK1/2 inhibitor3.28 (2.85–3.78) · n=198 Reporting signal.
- DoxorubicinAnthracycline2.98 (2.62–3.38) · n=238 Reporting signal.
- PonatinibBCR-ABL TKI2.98 (2.00–4.45) · n=24 Reporting signal.
- SunitinibVEGFR TKI2.87 (2.34–3.52) · n=93 Reporting signal.
- DocetaxelTaxane2.68 (2.29–3.15) · n=151 Reporting signal.
- BendamustineAlkylator2.45 (1.85–3.25) · n=49 Reporting signal.
- CapecitabinePyrimidine analog (oral 5-FU)2.21 (1.90–2.57) · n=168 Reporting signal.
- FruquintinibVEGFR TKI2.14 (1.02–4.48) · n=7 Reporting signal, fragile (few reports).
- PembrolizumabPD-1 checkpoint inhibitor2.10 (1.80–2.46) · n=161 Reporting signal.
- SorafenibVEGFR TKI1.86 (1.31–2.63) · n=32 Reporting signal.
- ErlotinibEGFR TKI1.85 (1.29–2.65) · n=30 Reporting signal.
- IxazomibProteasome inhibitor1.46 (1.05–2.04) · n=35 Reporting signal.
- PazopanibVEGFR TKI1.38 (0.97–1.97) · n=31 No reporting signal.
- NivolumabPD-1 checkpoint inhibitor1.17 (0.96–1.43) · n=96 No reporting signal.
- IpilimumabCTLA-4 checkpoint inhibitor1.04 (0.76–1.43) · n=38 No reporting signal.
- LenalidomideImmunomodulatory drug (IMiD)1.02 (0.91–1.13) · n=360 No reporting signal.
- Trastuzumab emtansine (T-DM1)Antibody-drug conjugate (HER2/DM1)0.71 (0.29–1.71) · n=5 No reporting signal.
- NintedanibVEGFR/FGFR/PDGFR TKI0.66 (0.41–1.04) · n=18 No reporting signal.
- Ziv-afliberceptVEGF trap0.59 (0.36–0.96) · n=16 No reporting signal.
- OlaparibPARP inhibitor0.39 (0.19–0.82) · n=7 No reporting signal.
- TislelizumabPD-1 immune checkpoint inhibitor0.32 (0.08–1.27) · n=2 No reporting signal.
- Lutetium-177 DotatateRadioligand therapy (PRRT)0.21 (0.03–1.46) · n=1 No reporting signal.
- AxitinibVEGFR TKI0.06 (0.01–0.43) · n=1 No reporting signal.
reporting odds ratio (log) — no signal left of the dashed line at 1.0
No ratio — no TMA reports, or too few (count in brackets): Doxifluridine, Tegafur-uracil (UFT)
No ratio — under 50 FAERS reports in total: Carmofur (HCFU), Daraxonrasib, Ivonescimab
Not matched in FAERS (the name cannot be told apart from other products): Interferon-α
All 43 agents documented with TMA in the atlas are shown whether or not FAERS flags them, plus the 54 agents FAERS flags that the atlas does not document (marked “FAERS only”; the strongest 10 until you show all). Class composites (mTOR inhibitors (everolimus · temsirolimus); VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib)) are not asked of FAERS; their member agents are ranked individually. 80 carry a reporting signal (filled dot: 95% CI lower bound above 1, on at least 50 reports for the agent); a signal on fewer than 10 reports of the disorder is hollow, on a dashed whisker. Grey marks are ratios that do not clear it. Signals are listed first, each group by ROR. n = reports of the disorder for the agent. openFDA FAERS, as of 2026-11-15. A reporting signal, not incidence or causation, and no signal is not evidence of safety. Layout after the single-event rankings of Klomjit, Gupta et al.
How anti-cancer drugs cause thrombotic microangiopathy
One lesion, two mechanistic routes — direct endothelial toxicity and VEGF withdrawal — converging on the glomerular capillary. Scroll to follow the injury from the endothelial surface to the sheared red cells on the smear.
At the bedside
VEGF-TMA deep dive →TMA is a final common pathway — the workup turns on the cause. Narrow the differential, then estimate the pretest probability of TTP before reaching for plasma exchange. After hematopoietic cell transplant, see the dedicated TA-TMA page.
What's driving this TMA?
Thrombotic microangiopathy is a final common pathway — the treatment turns entirely on the cause. Select a driver.
PLASMIC score
Bendapudi 2017 · PMID 28259520Pretest probability of severe ADAMTS13 deficiency (TTP) in an adult with thrombotic microangiopathy. Answer each feature — a Yes scores one point. The score appears once all seven are answered.
Answer all seven criteria to see the score and risk band (0/7 answered).
Educational aid only — not medical advice. The PLASMIC score supplements, and does not replace, ADAMTS13 activity testing and clinical judgment.
Management approach
Full framework →Stop the culprit drug — the single most important step — with supportive care; complement-pathway-directed therapy for severe, refractory, or complement-mediated cases.
Drug-level levers
- Discontinue the offending agent promptly; re-exposure risk is high.
- Distinguish dose-dependent/toxic TMA (e.g. mitomycin C, gemcitabine, VEGF inhibitors, carfilzomib) from complement-mediated TMA — the latter is the one most likely to respond to complement blockade.
- Switch out of class for ongoing therapy — drug-induced TMA tends to recur on rechallenge.
- Control hypertension aggressively.
Pharmacologic toolkit
- C5 inhibition (eculizumab, ravulizumab) — First-line complement blockade for severe or drug-discontinuation-refractory TMA; eculizumab achieved renal recovery in ~80% of reported drug-induced cases (gemcitabine, carfilzomib, bevacizumab). Ravulizumab is the longer-acting C5 alternative. Cover/vaccinate against encapsulated organisms before dosing.
- Narsoplimab (anti-MASP-2, lectin pathway) — Targets the lectin pathway driving transplant-associated (HSCT) TMA; its pivotal single-arm trial reported a 61% response. FDA-approved in late 2025 as Yartemlea (narsoplimab-wuug) — the first therapy indicated for HSCT-associated TA-TMA, in adults and children ≥2 years — though access/cost considerations apply and responses vary.
- Emerging complement inhibitors — Iptacopan (factor B), pegcetacoplan (C3), crovalimab and danicopan are under investigation; second-line selection after a suboptimal C5-inhibitor response is increasingly guided by complement biomarkers (e.g. sC5b-9).
- Supportive care — Transfusion, blood-pressure control, and dialysis as needed.
- Plasma exchange — Generally ineffective for drug-induced TMA (unlike TTP) and not routinely recommended.
When to biopsy
Consider when the diagnosis is unclear; but the peripheral smear (schistocytes), LDH, haptoglobin, and platelet count usually establish TMA noninvasively.
Monitoring
- · CBC, schistocytes, LDH, haptoglobin
- · Creatinine and blood pressure
- · Urine protein
- · Complement activation markers (e.g. sC5b-9) where complement-mediated TMA is suspected
Grounding
- Eculizumab in drug-induced TMA — scoping review, Thromb Res 2023 · PMID 36871347 ↗
- Narsoplimab (anti-MASP-2) for HSCT-associated TMA — pivotal trial, J Clin Oncol 2022 · PMID 35439028 ↗
- Complement as a target in HSCT-related TMA — review, Pharmaceuticals 2022 · PMID 35890144 ↗
- Biomarker-guided TA-TMA management — Front Med 2025 · PMID 40406401 ↗
Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.
What the guidelines say
All guidelines →Society and consensus recommendations that speak to thrombotic microangiopathy.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
Cited incidence across agents
Where the literature gives a representative thrombotic microangiopathy figure, the agents ranked highest first. Hover a dot for its cited note.
Offending agents
Signature offenders
13Agents for which thrombotic microangiopathy is the defining renal lesion.
Also associated
32Agents that cause thrombotic microangiopathy as a secondary pattern alongside a different signature lesion.